Antiverse

Antiverse is a Cardiff AI-driven techbio company designing therapeutic antibodies for hard-to-drug targets such as G-protein coupled receptors and ion channels. Its generative antibody-design platform combines proprietary datasets, machine learning and programmable cell-line engineering in a lab-in-the-loop workflow that designs, builds and validates epitope-specific antibodies in-house, with offices in Boston and Prague and partnerships with multiple top-20 pharma companies. In March 2026 Antiverse raised a $9.3 million Series A led by Soulmates Ventures with Innovation Investment Capital, DOMiNO Ventures and existing investors DBW, Kadmos Capital and i&i Biotech Fund, bringing total funding above $20 million, and announced a research agreement with the Cystic Fibrosis Foundation to design antibodies against extracellular CFTR. Sources: Business Wire 3 Mar 2026; FinSMEs.